Symbols / KYTX Stock $9.13 +0.72% Kyverna Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
KYTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Warner Biddle
Exch · Country NMS · United States
Market Cap 552.34M
Enterprise Value 297.50M
Income -161.31M
Sales —
FCF (ttm) -92.08M
Book/sh 3.85
Cash/sh 4.62
Employees 130
Insider 10d —
IPO Feb 09, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.20
PEG —
P/S —
P/B 2.37
P/C —
EV/EBITDA -1.77
EV/Sales —
Quick Ratio 7.65
Current Ratio 7.75
Debt/Eq 12.50
LT Debt/Eq —
EPS (ttm) -3.64
EPS next Y -2.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-26
ROA -35.47%
ROE -64.67%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 60.53M
Shs Float 35.15M
Insider Own 7.10%
Instit Own 72.90%
Short Float 8.24%
Short Ratio 6.17
Short Interest 4.23M
52W High 13.67
vs 52W High -33.25%
52W Low 1.92
vs 52W Low 375.26%
Beta 2.64
Impl. Vol. 74.22%
Rel Volume 0.73
Avg Volume 847.91K
Volume 614.95K
Target (mean) $29.60
Tgt Median $32.00
Tgt Low $20.00
Tgt High $33.00
# Analysts 5
Recom Strong_buy
Prev Close $9.06
Price $9.12
Change 0.72%
About

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.60
Mean price target
2. Current target
$9.13
Latest analyst target
3. DCF / Fair value
$-27.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.13
Low
$20.00
High
$33.00
Mean
$29.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-23 reit HC Wainwright & Co. Buy → Buy $20
2025-12-16 main Wells Fargo Overweight → Overweight $33
2025-12-04 main Morgan Stanley Overweight → Overweight $25
2025-10-30 main Wells Fargo Overweight → Overweight $31
2025-10-27 main HC Wainwright & Co. Buy → Buy $20
2025-10-08 main Wells Fargo Overweight → Overweight $27
2025-08-29 main HC Wainwright & Co. Buy → Buy $10
2025-08-20 init William Blair — → Outperform —
2025-05-27 up HC Wainwright & Co. Neutral → Buy $5
2025-04-03 main HC Wainwright & Co. Neutral → Neutral $4
2025-04-01 main Morgan Stanley Overweight → Overweight $20
2024-11-20 main HC Wainwright & Co. Neutral → Neutral $6
2024-11-15 main Wells Fargo Overweight → Overweight $24
2024-10-10 init UBS — → Buy $13
2024-09-19 reit HC Wainwright & Co. Neutral → Neutral $7
2024-08-15 main HC Wainwright & Co. Neutral → Neutral $7
2024-07-31 main JP Morgan Overweight → Overweight $33
2024-07-16 reit HC Wainwright & Co. Neutral → Neutral $8
2024-07-03 init HC Wainwright & Co. — → Neutral $8
2024-03-04 init JP Morgan — → Overweight $39
News
RSS: Latest KYTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 GRASSO MARC Chief Financial Officer — 10,000 $0.00 $0
2026-03-13 BIDDLE WARNER WESTON Chief Executive Officer — 58,000 $0.00 $0
2026-03-13 GEHCHAN NAJI M.D. Officer — 18,000 $0.00 $0
2026-02-24 MILLER ANDREW CRAIG Director — 11,006 $0.00 $0
2026-02-24 EMANY SRAVAN KUMAR Director — 11,006 $0.00 $0
2026-01-12 SHAW CHRISTI L Officer and Director — 54,301 $0.00 $0
2025-12-18 SEIDENBERG BETH C Director — 133,333 $7.50 $999,998
2025-12-18 WESTLAKE BIOPARTNERS FUND I, L.P. Beneficial Owner of more than 10% of a Class of Security — 133,333 $7.50 $999,998
2025-12-15 WALKER KAREN MARIE Chief Technology Officer — 23,998 $12.20 $292,776
2025-12-15 WALKER KAREN MARIE Chief Technology Officer — 23,998 $4.83 $115,910
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
7.03
Operating Revenue
0.00
0.00
0.00
-100.00%
7.03
Operating Expense
169.83
+19.09%
142.60
+128.51%
62.41
+71.40%
36.41
Research And Development
133.72
+18.89%
112.47
+125.29%
49.92
+75.77%
28.40
Selling General And Administration
36.11
+19.83%
30.13
+141.38%
12.48
+55.90%
8.01
General And Administrative Expense
36.11
+19.83%
30.13
+141.38%
12.48
+55.90%
8.01
Other Gand A
36.11
+19.83%
30.13
+141.38%
12.48
+55.90%
8.01
Total Expenses
169.83
+19.09%
142.60
+128.51%
62.41
+71.40%
36.41
Operating Income
-169.83
-19.09%
-142.60
-128.51%
-62.41
-112.38%
-29.38
Total Operating Income As Reported
-169.83
-19.09%
-142.60
-128.51%
-62.41
-112.38%
-29.38
EBITDA
-159.02
-27.01%
-125.20
-114.12%
-58.47
-110.51%
-27.78
Normalized EBITDA
-159.02
-27.01%
-125.20
-114.12%
-58.47
-110.51%
-27.78
Reconciled Depreciation
1.80
-15.66%
2.13
+24.96%
1.71
+62.42%
1.05
EBIT
-160.82
-26.30%
-127.33
-111.59%
-60.18
-108.75%
-28.83
Net Income
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Pretax Income
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Net Non Operating Interest Income Expense
8.61
-43.45%
15.22
+626.35%
2.10
+319.00%
0.50
Interest Expense Non Operating
0.49
+244.37%
0.14
-24.06%
0.19
+187.69%
0.07
Net Interest Income
8.61
-43.45%
15.22
+626.35%
2.10
+319.00%
0.50
Interest Expense
0.49
+244.37%
0.14
-24.06%
0.19
+187.69%
0.07
Interest Income Non Operating
9.09
-40.79%
15.36
+573.05%
2.28
+303.89%
0.56
Interest Income
9.09
-40.79%
15.36
+573.05%
2.28
+303.89%
0.56
Other Income Expense
-0.09
+5.56%
-0.09
-63.64%
-0.06
-511.11%
-0.01
Other Non Operating Income Expenses
-0.09
+5.56%
-0.09
-63.64%
-0.06
-511.11%
-0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Net Income From Continuing Operation Net Minority Interest
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Net Income From Continuing And Discontinued Operation
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Net Income Continuous Operations
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Normalized Income
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Net Income Common Stockholders
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Diluted EPS
-3.64
-9.31%
-3.33
-125.19%
-1.48
-32.06%
-1.12
Basic EPS
-3.64
-9.31%
-3.33
-125.19%
-1.48
-32.06%
-1.12
Basic Average Shares
44.26
+15.46%
38.33
-6.09%
40.82
+58.20%
25.80
Diluted Average Shares
44.26
+15.46%
38.33
-6.09%
40.82
+58.20%
25.80
Diluted NI Availto Com Stockholders
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
293.83
-3.55%
304.64
+305.14%
75.19
+12.36%
66.92
Current Assets
282.95
-2.63%
290.60
+379.03%
60.66
+13.92%
53.25
Cash Cash Equivalents And Short Term Investments
279.25
-2.35%
285.98
+396.98%
57.54
+12.12%
51.32
Cash And Cash Equivalents
124.09
+28.43%
96.62
+178.87%
34.65
-8.18%
37.73
Other Short Term Investments
155.16
-18.06%
189.36
+727.04%
22.90
+68.51%
13.59
Other Current Assets
3.70
-19.95%
4.62
+48.09%
3.12
+61.79%
1.93
Total Non Current Assets
10.87
-22.58%
14.04
-3.35%
14.53
+6.28%
13.67
Net PPE
5.42
-49.15%
10.66
+0.43%
10.61
-14.72%
12.44
Gross PPE
9.17
-36.01%
14.33
+9.39%
13.10
-6.84%
14.06
Accumulated Depreciation
-3.75
-2.12%
-3.67
-47.59%
-2.49
-53.77%
-1.62
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.30
-37.33%
2.07
+172.11%
0.76
+13.10%
0.67
Other Properties
6.94
-39.36%
11.44
-2.17%
11.69
-9.57%
12.93
Leases
0.94
+14.01%
0.82
+27.29%
0.65
+41.45%
0.46
Other Non Current Assets
5.45
+60.98%
3.39
-13.59%
3.92
+218.26%
1.23
Total Liabilities Net Minority Interest
61.55
+61.73%
38.06
-81.58%
206.59
+46.60%
140.92
Current Liabilities
36.49
+8.09%
33.76
+69.98%
19.86
+66.13%
11.95
Payables And Accrued Expenses
22.53
-9.65%
24.93
+76.49%
14.13
+83.44%
7.70
Payables
5.31
+14.75%
4.62
+6.10%
4.36
+200.34%
1.45
Accounts Payable
5.31
+14.75%
4.62
+6.10%
4.36
+200.34%
1.45
Current Accrued Expenses
17.22
-15.20%
20.31
+107.89%
9.77
+56.30%
6.25
Pensionand Other Post Retirement Benefit Plans Current
9.99
+104.59%
4.88
+73.65%
2.81
+99.29%
1.41
Current Debt And Capital Lease Obligation
3.97
+0.74%
3.94
+34.93%
2.92
+28.24%
2.28
Current Capital Lease Obligation
3.97
+0.74%
3.94
+34.93%
2.92
+28.24%
2.28
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Other Current Liabilities
—
—
3.52
+522.83%
0.56
Total Non Current Liabilities Net Minority Interest
25.06
+482.59%
4.30
-97.70%
186.73
+44.79%
128.97
Long Term Debt And Capital Lease Obligation
25.06
+482.59%
4.30
-30.15%
6.16
-25.68%
8.29
Long Term Debt
24.74
—
—
—
Long Term Capital Lease Obligation
0.32
-92.56%
4.30
-30.15%
6.16
-25.68%
8.29
Non Current Deferred Liabilities
—
—
—
0.00
Non Current Deferred Revenue
—
—
—
0.00
Other Non Current Liabilities
—
—
—
0.01
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
180.57
+49.64%
120.67
Stockholders Equity
232.28
-12.87%
266.59
+302.89%
-131.40
-77.57%
-74.00
Common Stock Equity
232.28
-12.87%
266.59
+302.89%
-131.40
-77.57%
-74.00
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
60.39
+39.74%
43.21
+0.23%
43.12
+5.62%
40.82
Ordinary Shares Number
60.39
+39.74%
43.21
+0.23%
43.12
+5.62%
40.82
Additional Paid In Capital
657.00
+23.96%
530.00
+11317.54%
4.64
+172.10%
1.71
Retained Earnings
-424.83
-61.21%
-263.52
-93.70%
-136.04
-79.77%
-75.68
Gains Losses Not Affecting Retained Earnings
0.10
-7.62%
0.10
+2525.00%
0.00
+115.38%
-0.03
Other Equity Adjustments
0.10
-7.62%
0.10
+2525.00%
0.00
+115.38%
-0.03
Total Equity Gross Minority Interest
232.28
-12.87%
266.59
+302.89%
-131.40
-77.57%
-74.00
Total Capitalization
257.02
-3.59%
266.59
+302.89%
-131.40
-77.57%
-74.00
Working Capital
246.47
-4.04%
256.85
+529.44%
40.80
-1.19%
41.30
Invested Capital
257.02
-3.59%
266.59
+302.89%
-131.40
-77.57%
-74.00
Total Debt
29.03
+252.24%
8.24
-9.22%
9.08
-14.06%
10.56
Capital Lease Obligations
4.29
-47.96%
8.24
-9.22%
9.08
-14.06%
10.56
Net Tangible Assets
232.28
-12.87%
266.59
+302.89%
-131.40
-77.57%
-74.00
Tangible Book Value
232.28
-12.87%
266.59
+302.89%
-131.40
-77.57%
-74.00
Non Current Accrued Expenses
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-153.71
-34.54%
-114.25
-117.99%
-52.41
-45.13%
-36.11
Cash Flow From Continuing Operating Activities
-153.71
-34.54%
-114.25
-117.99%
-52.41
-45.13%
-36.11
Net Income From Continuing Operations
-161.31
-26.54%
-127.48
-111.17%
-60.37
-108.93%
-28.89
Depreciation Amortization Depletion
1.80
-15.66%
2.13
+24.96%
1.71
+62.42%
1.05
Depreciation And Amortization
1.80
-15.66%
2.13
+24.96%
1.71
+62.42%
1.05
Other Non Cash Items
2.97
+16.82%
2.54
+47.91%
1.72
+21.90%
1.41
Stock Based Compensation
10.08
+20.62%
8.36
+276.44%
2.22
+138.97%
0.93
Asset Impairment Charge
0.65
0.00
—
—
Operating Gains Losses
0.06
—
—
—
Gain Loss On Sale Of PPE
0.06
0.00
—
0.00
Change In Working Capital
-1.08
-113.69%
7.86
+129.47%
3.42
+133.16%
-10.33
Change In Prepaid Assets
0.89
+159.49%
-1.50
-25.92%
-1.19
-31.13%
-0.91
Change In Payables And Accrued Expense
2.35
-82.86%
13.71
+68.37%
8.14
+1301.18%
-0.68
Change In Accrued Expense
1.81
-86.07%
12.98
+219.53%
4.06
+399.70%
-1.35
Change In Payable
0.54
-26.22%
0.74
-81.97%
4.08
+503.10%
0.68
Change In Account Payable
0.54
-26.22%
0.74
-81.97%
4.08
+503.10%
0.68
Change In Other Working Capital
—
—
—
-7.03
Change In Other Current Assets
-0.98
+49.87%
-1.96
-5.73%
-1.85
-190.27%
-0.64
Change In Other Current Liabilities
-3.34
-39.18%
-2.40
-42.88%
-1.68
-55.75%
-1.08
Investing Cash Flow
40.02
+124.87%
-160.90
-1731.55%
-8.79
+37.68%
-14.10
Cash Flow From Continuing Investing Activities
40.02
+124.87%
-160.90
-1731.55%
-8.79
+37.68%
-14.10
Net PPE Purchase And Sale
0.07
+102.95%
-2.21
-255.07%
-0.62
+19.14%
-0.77
Purchase Of PPE
-0.01
+99.77%
-2.21
-255.07%
-0.62
+19.14%
-0.77
Sale Of PPE
0.07
0.00
—
—
Capital Expenditure
-1.13
+48.62%
-2.21
-255.07%
-0.62
+19.14%
-0.77
Capital Expenditure Reported
-1.13
0.00
—
—
Net Investment Purchase And Sale
41.08
+125.88%
-158.70
-1843.86%
-8.16
+38.75%
-13.33
Purchase Of Investment
-364.62
+25.59%
-490.00
-793.39%
-54.85
+2.92%
-56.49
Sale Of Investment
405.70
+22.46%
331.30
+609.68%
46.68
+8.15%
43.17
Financing Cash Flow
141.17
-58.12%
337.11
+480.05%
58.12
+389.21%
11.88
Cash Flow From Continuing Financing Activities
141.17
-58.12%
337.11
+480.05%
58.12
+389.21%
11.88
Net Issuance Payments Of Debt
-0.81
+15.48%
-0.96
-22.41%
-0.78
-213.65%
-0.25
Repayment Of Debt
-0.81
+15.48%
-0.96
-22.41%
-0.78
-213.65%
-0.25
Long Term Debt Payments
-0.81
+15.48%
-0.96
-22.41%
-0.78
-213.65%
-0.25
Net Long Term Debt Issuance
-0.81
+15.48%
-0.96
-22.41%
-0.78
-213.65%
-0.25
Net Common Stock Issuance
115.91
-66.03%
341.17
0.00
—
Proceeds From Stock Option Exercised
1.99
+667.18%
0.26
-59.84%
0.65
+268.57%
0.17
Net Other Financing Charges
-0.62
+81.58%
-3.36
-104.19%
-1.65
—
Changes In Cash
27.47
-55.66%
61.96
+2113.68%
-3.08
+91.97%
-38.33
Beginning Cash Position
97.17
+175.97%
35.21
-8.04%
38.29
-50.03%
76.62
End Cash Position
124.64
+28.27%
97.17
+175.97%
35.21
-8.04%
38.29
Free Cash Flow
-154.84
-32.97%
-116.45
-119.60%
-53.03
-43.79%
-36.88
Interest Paid Supplemental Data
0.41
+192.25%
0.14
-24.06%
0.19
+187.69%
0.07
Amortization Of Securities
-6.89
+10.13%
-7.66
-587.35%
-1.11
-292.61%
-0.28
Common Stock Issuance
115.91
-66.03%
341.17
0.00
—
Issuance Of Capital Stock
140.61
-58.79%
341.17
+469.57%
59.90
+401.09%
11.95
Net Preferred Stock Issuance
24.70
0.00
-100.00%
59.90
+401.09%
11.95
Preferred Stock Issuance
24.70
0.00
-100.00%
59.90
+401.09%
11.95
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category